Germany Clinical Trial Supplies Market Segmentation Analysis Report 2021-2026 | Germany Clinical Trial Supplies Industry Analysis on Size, Share, Growth, Trends, Demand, Competitive Analysis, and Forecast Report 2021-2026

Published: September 2020  |  Report ID:1012  | Pages: 150

Germany Clinical Trial Supplies Market – Research Overview:

Germany Clinical Trial Supplies Market was valued at USD 120 million in 2020 and it is expected to grow more during the forecast period. Growing dominance of diseases, such as HIV, and Cancer, along with increasing number of clinical trials are expected to support the growth of the clinical trials market. Gain in biologics and bio similar drugs are also estimated to give near the clinical trials market growth. About half of the phase I clinical trials go on outsourced and the phenomena is expected to grow further on account of globalization of clinical trials.

Complication in the conveyance of clinical trials is driving the clinical supply growth courier companies, and comparator sourcing businesses with courier companies screening substantial growth. Increasing R&D in biologics and bio similar will lead to an upsurge in demand for cold chain services. Furthermore, demand for biosimilars in Germany will showcase the development in cold chain supply.

Germany clinical trial supplies market is noticeable by the occurrence of well-known companies such as PAREXEL International Corporation, Almac Group Ltd., and Movianto GmbH. Substantial investments in R&D, collaborations, and strategic partnerships are some of the key approaches accepted by most of the market key players. For example, in 2016, The Almac Group collaborated with Exostar LLC, a prominent supplier of cloud-based and identity access management solutions to offer Federated Authentication access and Single SignOn to eClinical claims that implemented to care clinical trials.

The collaboration has aided support Almac’s global client base. In May 2017, Catalent Pharma Solutions stated a contract with Therachon AG, a biotechnology company, to livelihood preclinical, as well as clinical, enlargement of novel protein TA-46 for the treatment of achondroplasia, a mutual type of short-limbed unusually.

Germany Clinical Trial Supplies Market – Segmentation:

According to the research reports, the Germany Clinical Trials Market is segmented By Phase, By Product & Services, By End user, and By Therapeutic Use. Depends on the segment by Phase, it is sub divided into Phase I, Phase II, Phase III. Based on Product & Services, it is further classified into Manufacturing, Storage and Distribution, and Supply chain Management (SCM). Based on Segmentation by End-use, it is divided in Pharmaceutical, Biologics, Medical Devices, and Others. Based on by Therapeutic Use, the market is sub divided into Oncology, Central Nervous System (CNS), Cardiovascular, Infectious disease, metabolic disorders, and others.

Germany Clinical Trial Supplies Market – Key Players:

According to the research study by the Data Research Reports, the major players listed in Germany Clinical Trials market, are; Alamc Group (UK), PCI Services (US), Catalent, Inc. (US), Sharp Packaging Services (US), Parexel International Corporation (US), Biocair (UK), KLIFO A/S (Denmark), O&M Movianto (US), Capsugel (Switzerland), Thermo Fisher Scientific, Inc. (US), and UDG Healthcare Plc. (Ireland).

Germany Clinical Trial Supplies Market – Recent Trends:

In 2016, The Almac Group collaborated with Exostar LLC, a prominent supplier of cloud-based and identity access management solutions to offer Federated Authentication access and Single SignOn to eClinical claims that implemented to care clinical trials.

In May 2017, Catalent Pharma Solutions stated a contract with Therachon AG, a biotechnology company, to livelihood preclinical, as well as clinical, enlargement of novel protein TA-46 for the treatment of achondroplasia, a mutual type of short-limbed unusually.

  1. Preface

1.1 Market Definition and Scope

1.2 Base Currency, Base Year and Forecast Periods

1.3 Key Research Objectives

1.4 Research Highlights

  1. General Study Assumptions
  2. Research Methodology

3.1 Introduction

3.2 Secondary Research

3.3 Primary Research

3.4 Analysis Design

3.5 Study Timeline

  1. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Market Trends

  1. Supply Chain Analysis
  2. Company Strategy Analysis

6.1 Merger and Acquisition Analysis

6.2 Agreements, Collaborations and Joint Ventures

6.3 Regional Presence

6.4 New Product Launches

  1. Market Outlook

7.1 Technological Advancement

7.2 Pricing Analysis

7.3 Epidemiology

7.4 Product Landscape Analysis (Brand Tracking Analysis & Pipeline Analysis)

  1. Market Segmentation

8.1 Overview

8.2 Global Clinical Trials Market, By Phase, forecast year 2021-2026

8.2.1 Phase I

8.2.2 Phase II

8.2.3 Phase III

8.2.4 Phase IV

8.2.5 Market Size Estimations & Forecasts (2021-2026)

8.3.6 Y-o-Y Growth Analysis

8.3.7 Market Investment Opportunities Analysis

8.3 Global Clinical Trials Market, By Study Design, forecast year 2021-2026

8.3.1 Interventional

8.3.2 Observational

8.3.2 Expanded Access

8.3.3 Market Size Estimations & Forecasts (2021-2026)

8.3.4 Y-o-Y Growth Analysis

8.3.5 Market Investment Opportunities Analysis

8.4 Global Clinical Trials Market, By Indication, forecast year 2021-2026

8.4.1 Autoimmune/Inflammation

8.4.2 Pain management

8.4.3 Cardiovascular

8.4.4 CNS condition

8.4.5 Oncology

8.4.6 Diabetes

8.4.7 Obesity

8.4.8 Others

8.4.9 Market Size Estimations & Forecasts (2021-2026)

8.4.10 Y-o-Y Growth Analysis

8.4.11 Market Investment Opportunities Analysis

  1. Global Market Regional and Country Analysis, Forecast 2021-2026

9.1 Overview

9.2 Regional Trends

9.3 Impact Analysis

9.4 Key Findings

9.5 Global Clinical Trials Market,  by Region, 2021-2026

9.5.1 By Phase

9.5.2 By Sudy Design

9.5.3 By Indication

  1. Competitive Landscape Analysis

10.1 Market Player

10.1.1 Company Revenue

10.1.2 Business unit

10.1.3 Product Mapping

10.1.4 Geographical Locations

10.2 Company Share Analysis

  1. Strategic Analysis

11.1 PESTLE analysis

11.2 Porter’s Five analysis

11.2.1 Bargaining Power of Suppliers

11.2.2 Bargaining Power of Consumers

11.2.3 Threat of New Entrants

11.2.4 Threat of Substitute Products and Services

11.2.5 Competitive Rivalry within the Industry

  1. Company Profiles

12.1 Omnicare

12.1.1 Overview

12.1.2 Product Portfolio

12.1.3 Financial Details

12.1.4 SWOT Analysis

12.1.5 Market Strategies

12.2 Chiltern

12.3 PPD

12.4 Parexel

12.5 Kendle International Inc

12.6 Quintiles

12.7 ICON Plc

12.8 Charles River

  1. Market Guidance
  2. Appendix